BRIEF—China's Adlai Nortye opens first international site

Adlai Nortye, a private Chinese biopharmaceutical company, has announced the opening of its first ever international site in Boston, Massachusetts.

The Boston site is an "innovation center" dedicated to the development of innovative immuno-oncology drugs. The center will support clinical stage programs of the company and serve as a platform to better integrate Adlai Nortye into the global biopharmaceutical research and development industry.

"Today marks the first step in our overseas expansion," said Adlai Nortye chief executive Carsten Lu. "The establishment of our Boston site is not just a significant step for our company, but also a sign of our relentless commitment to developing innovative, world-class therapeutic solutions for patients."

The new Boston site will focus on novel discovery and translational medicine research, such as mechanistic and biomarker studies. The site will allow Adlai Nortye to expand its expertise in immuno-oncology.